Eledon Pharma To Present 24-Month Follow-Up Data From Eight Patients Enrolled In Phase 1b Trial Long-Term Extension Evaluating Tegoprubart In Kidney Transplantation At 2026 ASTS Winter Symposium

Data from eight participants continue to support safety and tolerability profile of tegoprubart

Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months

IRVINE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium, taking place January 23–25, 2026, in Scottsdale, Arizona.